Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management
January 03 2022 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
advancing a robust pipeline of oncology and neuroscience product
candidates that are designed to uniquely disrupt cellular signaling
dynamics, today announced the appointment of Rimma Steinhertz,
Ph.D., PMP to the newly created position of Vice President, Project
and Alliance Management, effective immediately. In this role, Dr.
Steinhertz will focus on working with Immuneering's leadership team
as it advances IMM-1-104 as a monotherapy into clinical trials in
2022 and working with potential future partners to advance
combination approaches with IMM-1-104 in select patient
populations.
“Rimma is a highly accomplished program leader and project
manager with decades of experience in preclinical and clinical
development for oncology and neurology,” stated Ben Zeskind, Ph.D.,
Co-Founder and Chief Executive Officer of Immuneering. “We welcome
Rimma to the team and look forward to leveraging her broad
expertise, deep knowledge of best practices in project management
for pharmaceutical R&D, and industry relationships as we
steadily advance our robust pipeline of novel product candidates,
including IMM-1-104.”
"Immuneering is employing a novel, differentiated approach to
drug development and I look forward to supporting the company's
commitment to operational excellence as it transitions from
preclinical development into human clinical trials," noted Dr.
Steinhertz.
Dr. Steinhertz joins Immuneering from Glenmark
Pharmaceuticals/Ichnos Sciences, Inc., where, since 2019, she
served as Executive Director, Global Program Leader, Portfolio
& Program Management, Oncology. Previously, from 2016 to 2019,
she was the Group Director, External Collaborations, Oncology at
Merck & Co., Inc., where she led a group of more than 30
clinical scientists and project managers supporting over 250
combination Phase 1-3 studies in 30+ indications for Keytruda® in
co-development with pharmaceutical and biotechnology companies,
academic and U.S. government entities. Prior to that, from 2006
through 2015, Dr. Steinhertz held positions of increasing
responsibility in the oncology group at Eisai, Inc., most recently
serving as Director, Program & Alliance Management, Oncology
Business Unit. Earlier in her career, from 2002 to 2006, she held
various positions at Johnson & Johnson Pharmaceutical Research
& Development, working on several pre-IND assets across
multiple indications.
Dr. Steinhertz earned the equivalent of a B.S. in chemical
engineering from the Moscow Technological Institute, a B.S. in
chemistry from Rhode Island College, a Ph.D. in medicinal/organic
chemistry from Boston College and a Project Management Professional
(PMP) from the Project Management Institute. She also completed a
Postdoctoral Fellowship in medicinal/organic chemistry at Harvard
University.
About Immuneering Corporation
Immuneering is a biopharmaceutical company with an emerging
pipeline focused on improving patient outcomes across a spectrum of
debilitating oncologic and neurologic diseases by applying its deep
knowledge of translational bioinformatics to every stage of the
drug development process. Immuneering has more than a decade of
experience in translational bioinformatics and generating insights
into drug mechanisms of action and patient treatment responses.
Building on this experience, Immuneering has developed a
disease-agnostic platform that enables the company to utilize human
data, novel biology and chemistry, and translational planning to
create and advance its wholly owned pipeline. Immuneering’s current
development programs in oncology are focused on providing potential
treatments for patients with solid tumors caused by mutations of
oncologic signaling pathways, including the MAPK pathway.
Immuneering’s lead product candidate, IMM-1-104, is designed to be
a highly selective dual-MEK inhibitor that further disrupts KSR for
the treatment of advanced solid tumors in patients harboring RAS
mutant tumors. Additionally, Immuneering has six other oncology
programs in the discovery stage that are designed to target either
the MAPK or mTOR pathway, and two neuroscience programs in the
discovery stage.
Forward-Looking Statements
This press release includes certain disclosures that contain
"forward-looking statements," including, without limitation,
statements regarding Immuneering’s progress toward drugs targeting
cancers driven by alterations that activate the RAS/MAPK pathway,
the treatment potential of IMM-1-104, including in combination with
other drugs, the timing of regulatory filings for IMM-1-104 with
the FDA and commencement of clinical trials for IMM-1-104.
Forward-looking statements are based on Immuneering’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, the risks
inherent in oncology and neuroscience drug development, including
target discovery, target validation, lead compound identification,
lead compound optimization, preclinical studies and clinical
trials. These and other risks and uncertainties are described more
fully in the section titled "Risk Factors" in the Company’s most
recent Form 10-Q filed with the U.S. Securities and Exchange
Commission (SEC) as well as in Immuneering’s subsequent filings it
makes with the SEC. Forward-looking statements contained in this
announcement are made as of this date, and Immuneering undertakes
no duty to update such information except as required under
applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Susan A. NoonanS.A. Noonan
Communications917-513-5303susan@sanoonan.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024